Oppenheimer Asset Management Inc. cut its position in Pediatrix Medical Group, Inc. (NYSE:MD – Get Rating) by 18.9% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 70,726 shares of the company’s stock after selling 16,457 shares during the quarter. Oppenheimer Asset Management Inc. owned about 0.09% of Pediatrix Medical Group worth $1,051,000 at the end of the most recent reporting period.
Other institutional investors have also added to or reduced their stakes in the company. Eagle Bay Advisors LLC boosted its stake in Pediatrix Medical Group by 122.5% in the 2nd quarter. Eagle Bay Advisors LLC now owns 1,595 shares of the company’s stock valued at $34,000 after purchasing an additional 878 shares during the period. Royal Bank of Canada lifted its position in shares of Pediatrix Medical Group by 97.3% during the 3rd quarter. Royal Bank of Canada now owns 2,166 shares of the company’s stock valued at $35,000 after acquiring an additional 1,068 shares during the period. Wipfli Financial Advisors LLC bought a new stake in shares of Pediatrix Medical Group during the 3rd quarter valued at $37,000. Sargent Bickham Lagudis LLC bought a new stake in shares of Pediatrix Medical Group during the 3rd quarter valued at $38,000. Finally, Point72 Hong Kong Ltd bought a new stake in shares of Pediatrix Medical Group during the 3rd quarter valued at $43,000. 95.99% of the stock is currently owned by institutional investors.
Pediatrix Medical Group Trading Up 5.1 %
Shares of MD stock opened at $13.69 on Friday. The stock has a market cap of $1.15 billion, a price-to-earnings ratio of 11.22, a PEG ratio of 0.59 and a beta of 1.74. The stock has a 50-day moving average of $14.61 and a 200-day moving average of $15.42. The company has a current ratio of 1.44, a quick ratio of 1.00 and a debt-to-equity ratio of 0.82. Pediatrix Medical Group, Inc. has a 1-year low of $12.84 and a 1-year high of $23.95.
Analysts Set New Price Targets
A number of research firms have recently weighed in on MD. StockNews.com began coverage on Pediatrix Medical Group in a research report on Thursday, March 16th. They set a “hold” rating for the company. Credit Suisse Group cut their target price on Pediatrix Medical Group from $27.00 to $23.00 and set an “outperform” rating for the company in a research report on Wednesday, February 22nd. Deutsche Bank Aktiengesellschaft lowered their price target on Pediatrix Medical Group from $15.50 to $14.00 in a report on Wednesday. Finally, Mizuho lowered their price target on Pediatrix Medical Group from $17.00 to $15.00 in a report on Wednesday. Four investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, Pediatrix Medical Group currently has a consensus rating of “Hold” and a consensus price target of $18.20.
About Pediatrix Medical Group
Pediatrix Medical Group, Inc engages in the provision of physician services. It includes newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care. The company was founded by Roger J. Medel in 1979 and is headquartered in Sunrise, FL.
Recommended Stories
- Get a free copy of the StockNews.com research report on Pediatrix Medical Group (MD)
- It’s Time To Check Into Booking.Com
- Shopify Delivers Growth And Efficiency; Shares Surge
- Advanced Micro Devices Bullish Reversal Is Still In Play
- Broadcom Shares Trade In Tight Range Ahead Of Q2 Earnings Report
- An Opportunity To Buy Starbucks Is Knocking On The Door
Receive News & Ratings for Pediatrix Medical Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pediatrix Medical Group and related companies with MarketBeat.com's FREE daily email newsletter.
